<DOC>
	<DOCNO>NCT02773927</DOCNO>
	<brief_summary>Presence metabolic syndrome ( MetS ) relation insulin resistance , obesity , dyslipidemia , systemic inflammation cardiovascular disease great concern . The study certain adipokines adiponectin demonstrate inverse association insulin resistance , especially Latin population low level adiponectin observe compare ethnic group . It appear important molecule involve limiting pathogenesis obesity-linked disorder may potential benefit marker evaluate effect possible intervention MetS component complication . Metformin treatment choice patient MetS , due low cost pharmacological comparable effect thiazolidinediones ( pioglitazone ) , decrease hyperinsulinemia , insulin resistance , free fatty acid triglyceride , produce well , moderate weight loss , improve lipid profile delay appearance diabetes mellitus subject abnormal fast glucose . A second choice lower risk would addition fiber like inulin , prebiotic , since demonstrate metabolic benefit lipid carbohydrate metabolism several mechanism propose induction lipogenic enzyme glucose , production short-chained fatty acid , glucose-dependent insulinotropic peptide ( GIP ) glucagon-like peptide-1 ( GLP-1 ) , growth Bifidobacterium . A good natural source inulin agave . It expect combination metformin plus agave inulin produce beneficial impact pharmacological synergism produce change pathophysiology MetS .</brief_summary>
	<brief_title>Combination Metformin/Inulin v Inulin Adiponectin Metabolic Syndrome</brief_title>
	<detailed_description>The main objective compare effect administration Metformin/agave inulin vs. Agave inulin adiponectin patient MetS . The investigator conduct double-blinded randomized trial , 4 group , group 10 male patient 40-80 year age METS diagnose International Diabetes Federation ( IDF ) criterion . Randomization determine group assignation 12-week trial , group consist : Group ( A ) Metformin plus agave inulin : 10 individual receive metformin dosis 500 mg per day ( 1 tablet 500 mg ) plus inulin dosis 10 mg per day ( 5 mg every 12 hour ) 12 week . Group ( B ) Metformin plus Placebo agave inulin : 10 individual receive Metformin dosis 500mg per day ( first bite second meal ) plus homologue placebo inulin ( calcinated magnesia ) dosis 10 mg every 24 hr ( 5 mg calcinated magnesia powder every 12 hour ) 12 week . Group ( C ) Agave inulin plus Placebo Metformin : 10 individual receive inulin dosis 10 mg every 24 hr ( 5 mg every 12 hour ) plus homologate placebo metformin ( calcinated magnesia ) dosis 500 mg per day ( first bite second meal ) 12 week . Group ( D ) Placebo Agave inulin plus Placebo Metformin : homologate placebo Inulin ( calcinated magnesia powder ) dosis 10 mg every 24 hr ( 5 mg every 12 hour ) plus homologate placebo metformin ( calcinated magnesia capsule ) dosis 500 mg per day ( first bite second meal ) 12 week . The clinical finding laboratory test include metabolic profile biosafety , determine baseline 12 week . Waist , body weight , body fat , body mass index ( BMI ) blood pressure determine baseline , follow final visit , likewise , blood sample obtain , centrifuge store -80° degree Celsius analyze within 30 day . The investigator assess glucose , total cholesterol , c-HDL , c-LDL , triglycerides enzymatic technique , adiponectin insulin ELISA . Insulin resistance ( IR ) estimate homeostasis model assessment ( HOMA ) formula HOMA ( fast insulin mcg/L x ( fast glucose ( mmol/L ) /22.5 ) Adverse event adherence treatment document every 4 week . Statistical analysis : Values express mean standard deviation . Mann-Whitney U Test , Wilcoxon exact test Kruskal-Wallis . A statistical significance set p &lt; 0.05 .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Magnesium Oxide</mesh_term>
	<criteria>Diagnosis metabolic syndrome IDF criterion person define metabolic syndrome must : Central obesity ( defined waist circumference* ethnicity specific value ) ≥80 cm female ≥90 cm male ; plus two follow four factor : Raised triglyceride ≥ 150 mg/dL ( 1.7 mmol/L ) specific treatment lipid abnormality Reduced HDL cholesterol &lt; 40 mg/dL ( 1.03 mmol/L ) males &lt; 50 mg/dL ( 1.29 mmol/L ) females specific treatment lipid abnormality Raised blood pressure systolic BP ≥ 130 diastolic BP ≥ 85 mm Hg treatment previously diagnose hypertension Raised fast plasma glucose ( FPG ) ≥ 100 mg/dL ( 5.6 mmol/L ) , previously diagnose type 2 diabetes Age range 40 80 year old Male patient Informed write consent Kidney disease Hepatic disease Thyroid disease Diabetes mellitus Ischemic heart disease Drug consumption Alcohol consumption 2 ounce daily Consumption drug intervene lipid glucose metabolism 2 month Blood pressure &gt; 160/100 mmHg . Lack adherence treatment ( adherence &lt; 80 % )</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Agave inulin</keyword>
	<keyword>Adiponectin</keyword>
	<keyword>Metabolic syndrome</keyword>
	<keyword>Metformin</keyword>
	<keyword>Insulin resistance</keyword>
</DOC>